Cargando…
Letrozole in advanced breast cancer: the PO25 trial
Tamoxifen has been a standard first-line endocrine therapy for post-menopausal women with hormone-responsive advanced breast cancer, but more than half of patients fail to respond and time to progression is less than 12 months in responders. The third-generation aromatase inhibitors were developed t...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2007
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001219/ https://www.ncbi.nlm.nih.gov/pubmed/17333340 http://dx.doi.org/10.1007/s10549-007-9527-6 |